Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Faculty Chair
Joyce O'Shaughnessy, MD
Texas Oncology, Dallas, TX, USA
Faculty Chair
Reshma Mahtani, DO
University of Miami Health System, Miami, FL, USA
Faculty Chair
Virginia Kaklamani, MD
UT Health San Antonio, San Antonio, TX, USA
Faculty Chair
Nusayba Ali Bagegni, MD
Washington University, St. Louis, MO, USA
Faculty Chair
Vijayakrishna Gadi, MD, PhD
University of Illinois, Champaign, IL
Faculty Chair
Melinda Telli, MD
Stanford University School of Medicine, Stanford, CA, USA
Faculty Chair
Ian Krop, MD
Dana-Farber Cancer, Boston, MA, USA
Faculty Chair
Sara Tolaney, MD
Dana-Farber Cancer, Boston, MA, USA
Faculty Chair
Sonya Reid, MD, MPH
Vanderbilt University Medical Center, Nashville, TN, USA
Faculty Chair
Reshma Mahtani, DO
Miami Cancer Institute, Miami Beach, FL, USA
More Information
- Las Vegas, NV
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- New York, NY
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
